Facebook
Twitter
LinkedIn
ForwardInfluenza Update! Advanced Practice Pearls on Treatment
1.0 NAPNAP Contact Hour, 0.5 contain Pharmacology. This continuing education activity is offered at a reduced rate to NAPNAP Members. This continuing education activity is free for NAPNAP Members and for non- members.
Overview
What’s new in treating influenza? Dr. Charles Vega and Dr. Paul Auwaerter will discuss the latest evidence regarding the use of antiviral agents, reviewing their ability and efficacy to reduce influenza transmission. The use of these agents for patients with influenza who are at normal or high risk for complications will also be discussed.
Provider
National Association of Pediatric Nurse Practitioners
Educational Partner
Vindico Medical Education
Support Statement
This activity is supported by an educational grant from Genentech, Inc.
Target Audience
This program is designed for pediatric nurse practitioners and other health care professionals involved in the management of patients with influenza.
Learning Objectives
Upon successful completion of this activity, participants should be better able to:
- Apply the latest evidence into practice regarding the use of antiviral agents for the treatment of patients with influenza who are at normal or high risk for complications.
- Incorporate the use of antiviral agents for influenza treatment based on their efficacy and ability to reduce the transmission of the disease.
Accreditation and Credit Designation
This program is accredited for 1.0 NAPNAP CE contact hours of which 0.5 contain pharmacology (Rx) content per the National Association of Pediatric Nurse Practitioners Continuing Education Guidelines. This enduring material is approved for 1 year from the date of original release, July 31, 2020 to July 31, 2021.
Unlabeled and Investigational Usage
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Disclaimer – Vindico Medical Education
The material presented at or in any Vindico Medical Education and National Association of Pediatric Nurse Practitioners continuing education activity does not necessarily reflect the views and opinions of Vindico Medical Education and National Association of Pediatric Nurse Practitioners. Neither Vindico Medical Education, National Association
of Pediatric Nurse Practitioners, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all
information before treating patients or utilizing any product.
Notice
Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program director and the Office of Medical Affairs and Compliance. This activity is supported by an educational grant from Genentech, Inc. Vindico Medical Education has been given meeting space to provide an educational offering during NAPNAP’s National Conference. NAPNAP’s approval of continuing education credit does not imply product endorsement.
Participants are forbidden to reproduce, republish, redistribute, or resell this course in any other form. For copyright-related questions, please email your question to: ce@napnap.org
Copyright Statement
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and National Association of Pediatric Nurse Practitioners (NAPNAP) continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and National Association of Pediatric Nurse Practitioners (NAPNAP). Neither Vindico Medical Education and National Association of Pediatric Nurse Practitioners (NAPNAP), nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.
CE Questions?
Contact us at CME@VindicoCME.com
Keywords: Influenza, antiviral, treatment
Disclosures
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control.
Speakers for Influenza Update! Advanced Practice Pearls on Treatment, have provided the following disclosure information, which is accurate at the time of release.
Activity Chair
Charles P. Vega, MD, FAAFP
Health Sciences Clinical Professor, Department of Family Medicine
Executive Director, Program in Medical Education for the Latino Community
Assistant Dean for Culture and Community Education
University of California, Irvine
Irvine, CA
Disclosures: No relevant financial relationships to disclose.
Presentations:
- Treating Flu – What’s New?
- Case Discussion
Faculty
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
Disclosures: Consulting Fee: Advanced Biotherapeutics, DiaSorin
Ownership Interest: Johnson & Johnson
Presentation:
- Review of the Evidence on Treatment
Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.
Heather Keesing, MSN, RN, APRN
Disclosures: No relevant financial relationships to disclose.
Vindico Medical Education and National Association of Pediatric Nurse Practitioners Staff: No relevant financial relationships to disclose.
Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance, and National Association of Pediatric Nurse Practitioners.
This program is accredited by the National Association of Pediatric Nurse Practitioners (NAPNAP) for 1.0 NAPNAP CE contact hours, of which 0.5 are pharmacology (Rx) content.
This enduring material is approved for 1 year from the date of original release, July 31, 2020 to July 31, 2021.
How to Participate in This Activity and Obtain CE Credit
To participate in this CE activity, you must read the objectives, view the lectures, and complete the CE posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, NAPNAP will issue a NAPNAP CE Contact Hours Certificate.
Available Credit
- 1.00 Contact hours